Search research articles
Contact Us
Filters
Showing results (151-160 of 252) with videos related to
Page
of 26
Sort By:
American Journal of Clinical Pathology
|
July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
Katalin Kelemen, Loann C Peterson, Irene Helenowski, et al.
Leukemia & Lymphoma
|
April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
Olga Frankfurt, Shuo Ma, Leo Gordon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma
D A Macdonald, K Ding, M K Gospodarowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Vaccine
|
October 20, 2006
Mycobacterium bovis BCG as a delivery system for the RAP-1 antigen from Babesia bovis
M P Santangelo, D McIntosh, F Bigi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product
Neelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
Leukemia & Lymphoma
|
January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
British Journal of Haematology
|
April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
Blood
|
January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
British Journal of Haematology
|
April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family
Andrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 252) with videos related to
Sort By:
Page
of 26
American Journal of Clinical Pathology
|
July 17, 2008
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
Katalin Kelemen, Loann C Peterson, Irene Helenowski, et al.
Leukemia & Lymphoma
|
April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
Olga Frankfurt, Shuo Ma, Leo Gordon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma
D A Macdonald, K Ding, M K Gospodarowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2018
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M Evens, Ranjana H Advani, Irene B Helenowski, et al.
Vaccine
|
October 20, 2006
Mycobacterium bovis BCG as a delivery system for the RAP-1 antigen from Babesia bovis
M P Santangelo, D McIntosh, F Bigi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2015
Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product
Neelima Vidula, Marcelo Villa, Irene B Helenowski, et al.
Leukemia & Lymphoma
|
January 8, 2025
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, et al.
British Journal of Haematology
|
April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
Blood
|
January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
British Journal of Haematology
|
April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family
Andrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
Page
of 26